Luca Luzzi

Luca Luzzi

Auto-generated profile, based on publicly available information

Luca Luzzi

Thoracic Surgery Unit, University Hospital of Siena, Siena, Italy

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 October 2023 in European Journal of Surgical Oncology
Verified
Journal Article
Closed access
CCChiara Catelli
Chiara Catelli
RCRoberto Corzani
Roberto Corzani
EZE. Zanfrini
E. Zanfrini
Federico FranchiFederico Franchi
Federico Franchi
MGMarco Ghisalberti
Marco Ghisalberti
LLL. Luzzi
L. Luzzi

1 April 2021 in Cells
Verified
Journal Article
Open access
PDF file
laura bergantinilaura bergantini
laura bergantini
Miriana D'AlessandroMiriana D'Alessandro
Miriana D'Alessandro
EVElda De Vita
Elda De Vita
FPFelice Perillo
Felice Perillo
AFAntonella Fossi
Antonella Fossi
DBDavid Bennett
David Bennett
Background: The immune mechanisms occurring during acute rejection (AR) and chronic lung allograft dysfunction are a challenge for research and the balance between effector and regulatory cells has not been defined completely. In this study, we aimed to elucidate the interaction of effector cells, mainly Th17, Th1 and Th2, and regulatory cells including (CD4+CD25+CD127low/−) T reg cells and phenotypes of B regs, CD19+CD24hiCD38hi, CD19+CD24hiCD27hi and CD19+CD5+CD1d+. Methods: Bronchoalveolar lavage cells (BAL) and peripheral blood mononuclear cells (PBMCs) from stable lung transplanted (LTx )subjects (n = 4), AR patients (n = 6) and bronchiolitis obliterans syndrome (BOS) (n = 6) were collected at the same time. Cellular subsets were detected through flow cytometry. Results: A predominance of Th17 cells subtypes in the PBMCs and BAL and a depletion of Tregs, that resulted in decrease Treg/Th17 ratio, was observed in the AR group. CD19+CD24hiCD38hi Bregs resulted increased in BAL of AR patients. Th1 cells predominance and a reduction of Tregs cells was observed in BAL from AR patients. Moreover, multivariate analysis showed interdependences within studied variables revealing that effector cells and regulatory cells can effectively discriminate patients’ immunological status. Conclusions: In AR, BOS and stable lung transplant, regulatory and effector cells clearly demonstrated different pathways of activation. Understanding of the balance of T cells and T and B regulatory cells can offers insights into rejection.

SGSusanna Guerrini
Susanna Guerrini
DRDavide Del Roscio
Davide Del Roscio
MZMatteo Zanoni
Matteo Zanoni
PCPaolo Cameli
Paolo Cameli
Elena BargagliElena Bargagli
Elena Bargagli
LLLuca Luzzi
Luca Luzzi
Background: Lung cancer (LC) represents the main cause of cancer-related deaths worldwide, especially because the majority of patients present with an advanced stage of the disease at the time of diagnosis. This systematic review describes the evidence behind screening results and the current guidelines available to manage lung nodules. Methods: This review was guided by the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines. The following electronic databases were searched: PubMed, EMBASE, and the Web of Science. Results: Five studies were included in the systematic review. The study cohort included 46,364 patients, and, in this case series, LC was detected in 9028 patients. Among the patients with detected LC, 1261 died of lung cancer, 3153 died of other types of cancers and 4614 died of other causes. Conclusions: This systematic review validates the use of CT in LC screening follow-ups, and bids for future integration and implementation of nodule management protocols to improve LC screening, avoid missed cancers and to reduce the number of unnecessary investigations.

Verified
Journal Article
Open access
PDF file
IDIrene Dell'anno
Irene Dell'anno
Marcella BarbarinoMarcella Barbarino
Marcella Barbarino
EBElisa Barone
Elisa Barone
Antonio GiordanoAntonio Giordano
Antonio Giordano
LLLuca Luzzi
Luca Luzzi
SLStefano Landi
Stefano Landi
For malignant pleural mesothelioma (MPM) novel therapeutic strategies are urgently needed. In a previous study, we identified 51 putative cancer genes over-expressed in MPM tissues and cell lines. Here, we deepened the study on nine of them (ASS1, EIF4G1, GALNT7, GLUT1, IGF2BP3 (IMP3), ITGA4, RAN, SOD1, and THBS2) to ascertain whether they are truly mesothelial cancer driver genes (CDGs) or genes overexpressed in an adaptive response to the tumoral progression (“passenger genes”). Through a fast siRNA-based screening, we evaluated the consequences of gene depletion on migration, proliferation, colony formation capabilities, and caspase activities of four MPM (Mero-14, Mero-25, IST-Mes2, and NCI-H28) and one SV40-immortalized mesothelial cell line (MeT-5A) as a non-malignant model. The depletion of EIF4G1 and RAN significantly reduced cell proliferation and colony formation and increased caspase activity. In particular, the findings for RAN resemble those observed for other types of cancer. Thus, we evaluated the in vitro effects of importazole (IPZ), a small molecule inhibitor of the interaction between RAN and importin-β. We showed that IPZ could have effects similar to those observed following RAN gene silencing. We also found that primary cell lines from one out of three MPM patients were sensitive to IPZ. As EIF4G1 and RAN deserve further investigation with additional in vitro and in vivo studies, they emerged as promising CDGs, suggesting that their upregulation could play a role in mesothelial tumorigenesis and aggressiveness. Furthermore, present data propose the molecular pathways dependent on RAN as a putative pharmacological target for MPM patients in the view of a future personalized medicine.

6 July 2020 in Journal of Robotic Surgery
Verified
Journal Article
Closed access
PDF file
LLLuca Luzzi
Luca Luzzi
RCRoberto Corzani
Roberto Corzani
MGMarco Ghisalberti
Marco Ghisalberti
FMFabiola Meniconi
Fabiola Meniconi
LLLisa De Leonibus
Lisa De Leonibus
PPPiero Paladini
Piero Paladini

9 December 2020 in Investigational New Drugs
Verified
Journal Article
Open access
PDF file
IDIrene Dell'anno
Irene Dell'anno
SMSarah Martin
Sarah Martin
Marcella BarbarinoMarcella Barbarino
Marcella Barbarino
AMAlessandra Melani
Alessandra Melani
RSRoberto Silvestri
Roberto Silvestri
SLStefano Landi
Stefano Landi
Summary: Objectives Malignant pleural mesothelioma (MPM) is an occupational disease mainly due to asbestos exposure. Effective therapies for MPM are lacking, making this tumour type a fatal disease. Materials and Methods In order to meet this need and in view of a future “drug repositioning” approach, here we screened five MPM (Mero-14, Mero-25, IST-Mes2, NCI-H28 and MSTO-211H) and one SV40-immortalized mesothelial cell line (MeT-5A) as a non-malignant model, with a library of 1170 FDA-approved drugs. Results Among several potential compounds, we found that fludarabine (F-araA) and, to a lesser extent, risedronic acid (RIS) were cytotoxic in MPM cells, in comparison to the non-malignant Met-5A cells. In particular, F-araA reduced the proliferation and the colony formation ability of the MPM malignant cells, in comparison to the non-malignant control cells, as demonstrated by proliferation and colony formation assays, in addition to measurement of the phospho-ERK/total-ERK ratio. We have shown that the response to F-araA was not dependent upon the expression of DCK and NT5E enzymes, nor upon their functional polymorphisms (rs11544786 and rs2295890, respectively). Conclusion This drug repositioning screening approach has identified that F-araA could be therapeutically active against MPM cells, in addition to other tumour types, by inhibiting STAT1 expression and nucleic acids synthesis. Further experiments are required to fully investigate this.